Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it
will report financial results for the second quarter on Thursday, August 4, 2016, after the U.S. financial markets close.
Management will provide an update on the company, discuss second quarter 2016 results, and discuss expectations for the future
via conference call on Thursday, August 4, 2016 at 4:30 p.m. ET. To access the call, please dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start time and refer to conference ID 56306704. A replay of the call will be
available beginning at 7:30 p.m. ET on the day of the call. To access the replay, please dial 855-859-2056 (domestic) or
404-537-3406 (international), and refer to conference ID 56306704.
A live audio webcast of the call will be available on the Investors section of the company's website, www.alnylam.com. An archived webcast will be available on the Alnylam website approximately two hours after the
event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the
translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3
Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare
diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease
targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi
therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its
"Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative
medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi
therapeutic clinical programs – including 4 in late stages of development – across its 3 STArs. The company's demonstrated
commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche,
Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus
Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists
and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the
world's top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more
information about Alnylam's pipeline of investigational RNAi therapeutics, please visit www.alnylam.com.
Alnylam Pharmaceuticals, Inc.
Investors and Media
Christine Regan Lindenboom, 617-682-4340
or
Investors
Josh Brodsky, 617-551-8276
View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005080/en/